http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1907856-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ee29774a2319f6b75e64ac25b07d86f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-102 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5064 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2006-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a08dd4a2dfcdd8655e755518accd54fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6061cbab96fe935709f0129ce212754 |
| publicationDate | 2008-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1907856-A2 |
| titleOfInvention | Angiogenesis inhibition based upon icam 1 or junb expression levels |
| abstract | Methods for determining angiogenesis associated with a disease in a subject include the steps of, in a suitable test sample, determining expression levels of at least one gene selected from junB and ICAM 1. A statistically significant decrease in, or low level of, expression of one or both of the genes indicates the presence of angiogenesis associated with the disease in the subject. Preferably, the test sample includes endothelial cells. The method may further include determining the expression of THBSl and/or IGFBP3. Methods of determining angiogenesis in a subject may also include determining the level of acetylated histone H3 in the promote region of the IGFBP3 gene in a test sample. Pharmaceutical compositions for use in inhibiting angiogenesis include a DNA methyltransf erase inhibitor together with a pharmaceutically acceptable carrier and are in a form suitable for metronomic dosing. They may alternatively or additionally include a component allowing targeting to endothelial cells. Methods of preventing or inhibiting angiogenesis associated with a disease in a subject involve administering a therapeutically effective amount of a DNA methyltransf erase inhibitor. Treatment regimes, microarrays and screening methods are also described. |
| priorityDate | 2005-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 381.